Journal of Clinical Endocrinology & Metabolism, Vol 62, 577-582, Copyright © 1986 by Endocrine Society

ARTICLES

Opioid modulation of normal and pathological human chromaffin tissue

M Mannelli, M Maggi, ML DeFeo, M Boscaro, G Opocher, F Mantero, E Baldi and G Giusti

To evaluate whether opioid receptor blockade might modulate sympathetic- adrenal activity, we studied the effects of placebo or naloxone administration on plasma catecholamine (CA) levels in a group of 13 normal subjects and 15 hypertensive patients suspected to have a pheochromocytoma. Diagnostic evaluation confirmed the presence of pheochromocytoma in 9 patients. Among these, 4 had a unilateral epinephrine (E)-secreting tumor, 3 had bilateral E-secreting tumors due to multiple endocrine adenomatosis type IIa, and 2 had a unilateral norepinephrine (NE)-secreting tumor. In each subject studied, CA secretion was evaluated by calculating the area (0-30 min) under the plasma hormone curves after placebo or naloxone administration. In normal subjects naloxone caused a significant increase (P less than 0.005) of E secretion, whereas NE did not change. Similarly, in the group of hypertensive patients, E secretion increased after naloxone (P less than 0.01). In pheochromocytoma patients naloxone caused a significant increase in E (P less than 0.05) and NE (P less than 0.01) secretion from E-producing tumors but no increase in the patients with NE-secreting pheochromocytomas. The study suggests that CA secretion from normal and pathological chromaffin tissue is modulated by endogenous opioids; this modulation seems particularly evident in patients with E-secreting pheochromocytoma.

This article has been cited by other articles:

				E. Dermitzaki, A. Gravanis, M. Venihaki, C. Stournaras, and A. N. Margioris Opioids Suppress Basal and Nicotine-Induced Catecholamine Secretion Via a Stabilizing Effect on Actin Filaments Endocrinology, May 1, 2001; 142(5): 2022 - 2031. [Abstract] [Full Text]